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A B S T R A C T
Accurate and timely expression of specific genes guarantees the healthy development and function of the brain.
Indeed, variations in the correct amount or timing of gene expression lead to improper development and/or
pathological conditions. Almost forty years after the first successful gene transfection in in vitro cell cultures, it is
currently possible to regulate gene expression in an area-specific manner at any step of central nervous system
development and in adulthood in experimental animals in vivo, even overcoming the very poor accessibility of
the brain. Here, we will review the diverse approaches for acute gene transfer in vivo, highlighting their ad-
vantages and disadvantages with respect to the efficiency and specificity of transfection as well as to brain
accessibility. In particular, we will present well-established chemical, physical and virus-based approaches
suitable for different animal models, pointing out their current and future possible applications in basic and
translational research as well as in gene therapy.
1. Introduction
Proper development of the central nervous system (CNS) determines
its function and consequent behaviors. Accordingly, numerous gene
alterations during development lead to brain disorders characterized by
a variety of abnormal behaviors, often depending on which brain area is
mostly affected. On the other hand, gene alterations during adulthood
may also lead to a variety of brain-related diseases and neurodegen-
erative disorders that vary in their symptoms, depending on the af-
fected brain areas. This complexity highlights the need for temporal and
spatial regulation of specific genes for proper brain function.
Accordingly, the development of reliable techniques for gene transfec-
tion in vivo has recently attracted the attention of an increasing number
of researchers as a means to study and understand the roles of the
diverse genes underlying the basic mechanisms of CNS development
and function (basic research) and to study genes involved in CNS dis-
orders to find new possible treatments (translational research). In
particular, in recent years, basic research has benefited from new tools
for gene editing (e.g., CRISPR-Cas9 technology; Ahmad et al., 2018) and
neuronal-activity modulation (optogenetics and chemogenetics;
Dobrzanski and Kossut, 2017; Towne and Thompson, 2016), which
both need to be coupled to a nucleic acid delivery system. For trans-
lational research, a fast-growing field of study focuses on the possibility
of treating CNS disorders by manipulating gene expression (gene
therapy) rather than by classical pharmacology, which has proven
highly ineffective in the last 10 years (Gribkoff and Kaczmarek, 2017).
Thus, regardless of the final application, the development of novel
methods for modulating gene expression in vivo has acquired increasing
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importance in recent years. This modulation can be achieved either by
the generation of genetically modified animals or by acute procedures
for gene expression modulation. Here, we will only review the latter.
Generally, an acute modulation of gene expression requires a
transfection or transduction process (i.e., a procedure that introduces
foreign nucleic acids, such as DNA/RNA, into a cell) to produce ge-
netically modified cells or organisms by nonviral or viral methods, re-
spectively. Indeed, many molecules, such as nucleic acids and certain
drugs, are not able to diffuse through the lipophilic cell membrane due
to their physicochemical properties (e.g., hydrophilicity, charge) and/or
size. Thus, the support of specific carriers or chemical/physical stimu-
lation is often necessary to increase the efficiency of the transfection
process.
Although highly efficient, acute introduction of DNA into mamma-
lian cells in vitro was achieved a long time ago (Graham and van der Eb,
1973), for the last four decades, scientists have struggled to increase the
efficiency of this process in vivo (Crystal, 2014). For example, circu-
lating nucleic acids for transfection have a very short half-life in vivo
because they are degraded by circulating nucleases in the blood.
Moreover, targeting specific organs and cell types at discrete times is
generally challenging in vivo and is particularly difficult in the case of
the brain for a number of reasons. First, the brain is an isolated, in-
accessible environment due to the presence of the skull and the blood-
brain barrier (BBB), which separates circulating blood from the brain’s
extracellular fluid. Second, the brain contains several different areas
that are each characterized by specific functions, rendering area-spe-
cific transfection crucial in this organ. Third, the CNS contains hun-
dreds of billions of neuronal and glial cells characterized by high di-
versity (e.g., even among neurons, there is a wide variety of diverse
types with diverse functions). Finally, neurons are postmitotic cells that
do not divide, requiring a cell cycle-independent introduction of genetic
material.
Since almost ninety-five percent of the animals used in research are
mice and rats (Badyal and Desai, 2014), we will focus this review on
rodents. For a long time, the dominant approach for acute gene transfer
in vivo in rodents was the design of different viral vectors with in-
creasingly higher efficiency of transfection and tissue specificity (see
viral methods below). Nevertheless, due to limitations related to the
safety of viral gene transfer, many physical strategies have also been
adopted, such as electroporation and sonoporation (see physical
methods below). However, physical methods require strong conditions
(e.g., strong electric field or ultrasound) for efficient transfection, and
thus a range of synthetic carriers for nucleic acids suited for chemical
transfection have also been created (see chemical methods below; Yin
et al., 2014). In recent years, different methods have also been com-
bined (e.g., physical and chemical methods or viruses and physical
methods) to try to overcome the shortcomings of one method vs the
other while taking advantage of the positive features of both.
In this review, we describe the currently available methods for the
delivery of nucleic acids to the CNS in vivo. First, we focus on chemical
methods, which include a wide selection of nucleic acid carriers that
allow crossing of the cell membrane. Second, we describe physical
methods, which take advantage of physical forces to increase mem-
brane permeability and possibly direct nucleic acids to the desired lo-
cation. Third, we address viral-based techniques, which explore the
intrinsic transfection ability of viruses. Interestingly, all of the described
techniques are very different, but they each present some level of
overlap, creating a great portfolio to choose from when designing di-
verse experiments with gene transfer in vivo. Here, we will note the
advantages and disadvantages of each described method and will in-
dicate their best-suited applications.
2. Chemical methods for transfection
Chemical methods of transfection are a set of techniques that rely on
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essential for transfection of the exogenous nucleic acids of interest
(Table 1). In particular, chemical carriers are prepared to favor the
formation of complexes with the nucleic acids and internalization by
endocytosis in the target cells. There, the genetic material is released
into the cytoplasm through endosomal escape and subsequently enters
the nucleus for transcription into messenger RNA (mRNA), followed by
translation into functional proteins in the cytoplasm (Fig. 1). Chemical
methods often have good gene-packaging capacity and low im-
munogenicity and toxicity, and they are relatively safe for the operator
(Zhi et al., 2018). Nevertheless, most chemical methods have low effi-
ciency, and they still rely on invasive methods of administration for in
vivo applications (e.g., intrathecal/intraventricular injections). Only
recently, the rapid development of materials science and nanoscience
has allowed the construction of more efficient chemical vectors for in
vivo transfection; these vectors are useful for not only basic research but
also the biomedical field (Glover et al., 2005; Lu and Jiang, 2017;
Ramamoorth and Narvekar, 2015; Yin et al., 2014). Here, we will focus
on three main groups of chemicals that are often used as vectors.
2.1. Lipids
The use of lipid carriers for transfection (i.e., lipofection) for in vitro
cell delivery has been widespread since the 1980s (Fraley et al., 1980;
Lu et al., 1989). Cationic lipids – the most commonly used lipids – are
synthetic lipids with a positively charged hydrophilic domain con-
nected by a linker to a long lipophilic tail. During transfection, the
negatively charged phosphate on the backbone of the nucleic acids
interacts with the hydrophilic domain on the lipid, creating a structure
called lipoplex (2–200 nm in diameter; (Higuchi et al., 2006; Inoh et al.,
2017; Ramamoorth and Narvekar, 2015; Ross and Hui et al., 1999)).
Once the lipoplex reaches the cell membrane, it is internalized by en-
docytosis, and the genetic material is then released from the endosomes
inside the cell (Nayerossadat et al., 2012; Fig. 1). Although the highly
positive charge on the surface of the lipids protects the genetic material
from cleavage by circulating endonucleases (Ramamoorth and
Narvekar, 2015), lipid-based vectors still suffer from a short half-life in
vivo because. This is due to the rapid degradation of lipid particles by
the reticuloendothelial system, which is composed of phagocytic cells
located in connective tissues (Nayerossadat et al., 2012; Petschauer
et al., 2015; Song et al., 2014). To overcome this issue, the DNA and
cationic lipid mixture is often supplemented with so-called helper lipids
(the most common being polyethylene glycol (PEG) and 1,2-dioleoyl-
phosphatidyl-ethanolamine (DOPE)). These are neutral lipids that in-
crease the lipoplex’s stability, thus increasing its serum half-life.
Moreover, the addition of helper lipids also increases the fusion be-
tween the lipid particle and the cell membrane and facilitates the
movement of genetic material between the endosomes and the cell
nucleus (Hassani et al., 2005; Nayerossadat et al., 2012; Yin et al.,
2014; Zhi et al., 2018). Finally, depending on the composition of the
cationic lipid mixture and the concentration of the genetic material,
lipoplexes may assume different tertiary structures that may favor
transfection efficiency. This structural variation is mainly due to dif-
ferent charge distributions on their surface and different areas of in-
teraction with the cell. For example, the hexagonal phases of a lipoplex
can spontaneously release the DNA content when these lipoplexes are in
contact with an anionic vesicle, whereas a multilamellar vesicular
structure (where the genetic material is sandwiched between lipid
multilayers) tends not to release its contents. Interestingly, the transi-
tion from multilamellar to hexagonal structures is favored by the ad-
dition of DOPE to the lipid-DNA mixtures (Dan, 2015; Ma et al., 2007).
Due to all these practices that increase transfection efficiency, lipids
have proven to be efficient in vivo for gene transfection by direct in-
jection in the ventricle or brain of mice (Hassani et al., 2005; Roessler
and Davidson et al., 1994). Moreover, lipids have been used as a gene-
Fig. 1. Chemical methods of gene delivery.
Lipid-mediated gene transfer (left) occurs by
the interaction between the positively charged
surface of the carriers and the negatively
charged cell membrane. This interaction pro-
motes endocytosis, creating an endosome lipo-
complex. The complex is then degraded in the
cell cytoplasm, and the released DNA is trans-
ported to the nucleus. Nanoparticle-mediated
gene transfer (middle) occurs by the nano-
particles binding to receptors on the cell sur-
face, followed by endocytosis. During endo-
some degradation in the cell cytoplasm, the
DNA attached to the core of the nanoparticles is
released and transported to the nucleus.
Similar to lipid-mediated gene transfer,
polymer-mediated gene transfer (right) occurs
via charge differences between the carriers and
the cell membrane, which promotes binding
and endocytosis. During endosome degrada-
tion, the DNA is released from the polymer
structure and is transported to the nucleus.
After DNA transcription, the mRNA exits the
nucleus, and it is translated into a protein in
the cytoplasm.
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delivery method for the treatment of glioblastomas by intratumoral
injection (Cikankowitz et al., 2017; Lagarce and Passirani, 2016;
Pulkkanen and Yla-Herttuala, 2005).
Another structural arrangement that may occur among cationic li-
pids is a nanoemulsion. A lipid nanoemulsion (LNE) is a dispersion of
nanoparticles of lipids (100–400 nm in diameter) in a liquid phase that
is obtained in vitro by the addition of a surfactant agent to prevent the
lipids from coalescing into a macroscopic phase. The main advantages
of LNEs include easy processing, low costs and easy scale up to large-
scale production (Liu and Yu et al., 2010; Ramamoorth and Narvekar,
2015). LNEs have been successfully used in vitro, showing a higher ef-
ficiency than liposomes (Liu and Yu et al., 2010). The usage of na-
noemulsions in vivo is becoming more popular due to their low toxicity
and high stability (Ramamoorth and Narvekar, 2015). For example,
successful delivery of tumor necrosis factor alpha (TNF-α) small inter-
fering RNA (siRNA) to treat lipopolysaccharide (LPS)-induced neu-
roinflammation has been achieved in rats (Kim et al., 2010). Of note,
the small dimension of the nanoparticles has also allowed intranasal
delivery, a convenient way of overcoming the impermeability of the
BBB and preventing the action of blood-circulating nucleases that may
digest the DNA of interest (Yadav et al., 2016).
Lastly, lipid carriers have also been recently used in the form of solid
lipid nanoparticles (SLNs). SLNs are lipid nanospheres (70–230 nm in
diameter) with an outer hydrophilic shell made of a phospholipid
double layer and an inner core containing long-chained lipids, gen-
erating particles that are solid and stable at body temperature (Kaur
et al., 2008). In the last decade, there has been increased interest in the
use of these nanoparticles for gene delivery, mainly due to their sta-
bility and biocompatibility (Pathak et al., 2017). Interestingly, SLNs
were used to deliver siRNAs against c-met in a murine model of glio-
blastoma via intravenous injection in vivo, and the treatment showed
positive outcomes (Jin et al., 2011). This result highlights the fact that
SLNs are very stable and may cross the BBB, making them a very de-
sirable vector for in vivo gene transfection in the brain.
2.2. Nanoparticles
With the rapid development of nanotechnology in the last decade,
the use of nanoparticles as a gene-delivery tool has quickly grown. The
main advantage of this kind of carrier is its high stability, great pro-
tection against circulating nucleases and low risk of toxicity (Bharali
et al., 2005). Here, we will focus on the most studied nanoparticles.
2.2.1. Silica and gold nanoparticles
Silica (an oxide of silicon) is a very malleable material that finds
applications in all realms of science and engineering. Silica nano-
particles are spheres (30 nm in diameter) that can be relatively easily
made and modified during synthesis. In particular, silica nanoparticles
coated with organic amino acids can interact with nucleic acids and can
protect the genetic material from endonucleases. In vitro studies have
shown that upon phagocytosis, coated silica nanoparticles can then be
internalized, subsequently releasing DNA (Kneuer et al., 2000a, b).
Interestingly, silica nanoparticles have also been used to study the de-
velopment of newly born neurons in vivo by transfecting an EFGFR1-
coding plasmid in the subventricular zone of adult mice with no signs of
cell degeneration or systemic or brain-specific toxicity (Bharali et al.,
2005; Luo and Saltzman, 2006). However, a recent report showed signs
of neuroinflammation in rats following intranasal administration of
silica nanoparticles (Parveen et al., 2017). Further studies on the effect
of these vectors in the brain are necessary.
Gold nanoparticles are also used as vectors for gene delivery, as gold
has been extensively studied in a biological context due to its very low
toxicity and its capability to bind a wide array of organic molecules. In
particular, some in vitro studies have shown that gold nanoparticles
coated with organic cationic molecules are able to bind nucleic acids
and are endocytosed, providing efficient delivery of the genetic
material (Bishop et al., 2015; Connor et al., 2005; Ekin et al., 2014;
Jensen et al., 2013; Levy et al., 2010; Peng et al., 2016). In addition,
gold nanoparticles also display strong and tunable optical properties
that have been tested in vitro (Pissuwan et al., 2011; Wijaya and
Hamad-Schifferli, 2008). Interestingly, gold nanoparticles can possibly
cross the BBB, as tested in not only an in vitro model of the BBB (Bonoiu
et al., 2009) but also in vivo (Jensen et al., 2013). In particular, suc-
cessful transfection of a siRNA against the antiapoptotic gene Bcl2 L12
was achieved in glioma cells upon systemic injection of gold nano-
particles in mice. Notably, the siRNA showed little enzymatic de-
gradation (Jensen et al., 2013). Recently, gold nanoparticles functio-
nalized with PEG or other long organic molecules showed much higher
BBB permeability (Escudero-Francos et al., 2017; Takeuchi et al.,
2018). Remarkably, gold nanoparticles were also used to downregulate
α-synuclein in a murine model of Parkinson’s disease following in-
traperitoneal injection and had positive outcomes on anatomical land-
marks of Parkinson’s (Hu et al., 2018).
2.2.2. Fullerenes
Fullerenes are carbon molecules of various shapes and dimensions:
spherical fullerenes (SFs) are called Buckminster fullerenes, whereas
cylindrical fullerenes with a hollow core are called carbon nanotubes
(CNTs). The incredible properties of fullerenes, such as high thermal
and electrical conductivity, great strength, and rigidity, put these mo-
lecules at the forefront of the fast-developing nanoengineering industry
(Yang et al., 2006). Moreover, SFs can be functionalized with cationic
charges and thus can stably condense double-stranded DNA into glo-
bules (< 100 nm in diameter), which are protective against in-
tracellular and circulating nucleases. Nevertheless, the only known in
vivo application to date of SFs is the successful delivery of the Insulin 2
gene directly to the liver in mice with no signs of systemic toxicity
(Maeda-Mamiya et al., 2010). Finally, it has been reported that SFs are
able to cross the BBB, although there are no reports of their use to
deliver genes to the CNS (Quick et al., 2008).
Additionally, CNTs have been studied as a possible vector for gene
delivery. Nevertheless, applying their use to the biomedical realm has
proven difficult because CNTs are poorly soluble in water. One strategy
to increase their water solubility is functionalization of their surface.
Indeed, CNTs functionalized with peptides and conjugated to DNA or
RNA are able to successfully penetrate the cell membrane, and the
DNA-functionalized CNTs are able translocate to the nucleus in in vitro
systems (Lacerda et al., 2008; Pantarotto et al., 2004; Singh et al.,
2005). Nevertheless, the in vivo application of CNTs is still in its early
stages (Lacerda et al., 2008; Zhang et al., 2014). Notably, Khuloud et al.
transfected the brain cortex in a rat model of ischemia with CNTs
functionalized with siRNA for Caspase 3. This treatment successfully
decreased the apoptotic cells around the lesion, with amelioration of
motor deficits in the operated rats (Al-Jamal et al., 2011; Costa et al.,
2016). Thus, although the application of fullerenes in biology is still in
its infancy, it is clear that these carbon nanomolecules offer a new,
interesting perspective on the upcoming development of gene-delivery
vectors (Montellano et al., 2011)
2.3. Polymers
Polymers are macromolecules composed of repeated units. Similar
to lipoplexes, the polymers used for gene delivery have a positively
charged surface that interacts with the negatively charged backbone of
nucleic acids to form complexes called polyplexes. Among the polymer
materials used for transfection, polyethylenimine (PEI) is one of the most
effective vectors in vitro and in vivo (Pack et al., 2005). PEI is a syn-
thetic, water-soluble polymer (0.8 −1000 kDa in molecular weight),
and its structural complexity can vary from linear to highly branched
(Ewe et al., 2016; Ramamoorth and Narvekar, 2015). PEIs are inter-
nalized through phagocytosis by cells and can avoid endosome diges-
tion/degradation via a proton-sponge effect. Due to their highly positive
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charge (derived from the large number of partially protonated amino
groups that they possess), PEIs can stop the natural acidification of the
endosome, generating strong osmotic imbalances, ultimately causing
endosome rupture and release of the polymer and the conjugated ge-
netic material into the cytoplasm. Moreover, the highly positive charge
acts as a protective factor against the action of cytoplasmatic nucleases
(Ewe et al., 2016). Interestingly, many studies showed promising pro-
spects for the use of PEI in vivo. For example, in a classic study, PEI-
based vectors were used to successfully and safely deliver luciferase
DNA to the brain through intracortical and intrahippocampal injections
with no animal morbidity (Abdallah et al., 1996). Since then, PEI-based
vectors have been used to deliver genetic material to different CNS
regions, such as the spinal cord (Shi et al., 2003; Shimamura et al.,
2004), the cortex in a murine model of ischemia (Oh et al., 2017) and
stem cells located in the subventricular zone (Lemkine et al., 2002). The
delivery occurred by direct brain injection since PEI-based vectors were
believed not to cross the BBB (Lungwitz et al., 2005). Recently, a PEI-
based vector was used to successfully downregulate α-synuclein using a
specific siRNA in a rat model of Parkinson’s disease after one single
intraventricular injection (Helmschrodt et al., 2017).
To overcome the potential low BBB permeability, PEI was linked to
a peptide from the rabies virus (RVG), and this method was used to
successfully deliver microRNA to the brain in vivo following tail injec-
tion (Hwang et al., 2011). Moreover, PEI functionalized with PEG was
used to deliver a plasmid coding the gene CD200 in a mouse model of
multiple sclerosis (CD200 shows decreased expression in this condi-
tion). Notably, the PEI-based carrier functionalized with PEG was able
to cross the BBB (Nouri et al., 2017). Remarkably, the transfection of
hypoglossal motor neurons was achieved by retrograde axonal trans-
port, which followed the injection of PEI complexed with DNA into the
tongue of an experimental rat (Wang et al., 2001).
Despite the abovementioned successes, further use of PEI for in vivo
transfection has been hindered by the relatively high toxicity of this
polymer and its low rate of uptake by living cells, leading to low
transfection efficiency. Thus, in the past few years, attention has turned
to less toxic polymers, such as chitosans. Chitosans are natural polymers
made of randomly distributed β-(1-4)-linked D-glucosamine and N-
acetyl-D-glucosamine and are considered very attractive vectors for
gene delivery in vivo. Indeed, chitosans are nontoxic at all concentra-
tions and can be efficiently functionalized (Duceppe and Tabrizian,
2010; Ramamoorth and Narvekar, 2015). For example, PEGylated
chitosan polymers were used to deliver siRNA against Galectine-1 and
EGFR, two genes known to increase the resistance of glioblastoma cells
to treatment with temozolomide. The delivery, which was performed by
intratumoral injection, resulted in an increased survival rate of the
animals (Danhier et al., 2015). Although chitosan-based polymers
cannot readily cross the BBB, this issue was overcome by extensively
modifying the chitosan structure. In particular, chitosans were first
trimethylated, generating a trimethylated chitosan (TMC), which in-
creased the solubility and siRNA binding to the polymer. Subsequently,
PEG was conjugated to TMC. Similar to the reports for lipid-based
delivery methods, the addition of PEG increased the biocompatibility
and serum stability of the construct. Notably, upon intravenous ad-
ministration, the specific delivery of Cy5.5-siRNA (a fluorescent probe
used to visualize RNA) to the brain in vivo was obtained by adding a
fragment derived from a rabies virus glycoprotein to PEG-modified
TMC (Gao et al., 2014). Remarkably, chitosan-based vectors were used
to transfect HIV-infected astrocytes with siRNA against genes necessary
for viral replication, successfully halting the HIV infection. In this
study, the chitosan nanoparticles were conjugated to antibodies that
could bind to the transferrin receptor in the BBB strongly, increasing
the permeability of the brain to the vectors (Gu et al., 2017).
Another class of polymers is dendrimers, highly branched synthetic
polymers that have been growing in popularity in biomedical research.
This interest is mainly due to their well-defined structure and high
density of easily modifiable functional groups (Hu et al., 2016). Topo-
logically, dendrimers are composed of a core, and the branching is
organized around this core, forming a spherical structure that is usually
positively charged with modifiable functional groups on the surface.
Due to their high density of positive charges, dendrimers escape the
endosome through the “proton sponge mechanism”, similar to PEI-
based polymers (Hu et al., 2016). Among the large array of dendrimers,
the most commonly used and the best-characterized one is poly-
amidoamine (PAMAM; (Hu et al., 2016; Pack et al., 2005)). PAMAM
has been extensively used in vitro due to its low cytotoxicity (Eichman
et al., 2000). To increase gene transfer efficiency and biocompatibility,
many functionalizations of PAMAM have been performed; these func-
tionalizations include the substitution of positive charges with arginine
groups (Choi et al., 2004), PEG (Luo and Saltzman, 2006; Wang et al.,
2009), and pyridine/histidine (Hashemi et al., 2016) and the addition
of hydrophobic chains, including lauroyl (Santos et al., 2010). Never-
theless, as a positively charged hydrophilic molecule, PAMAM cannot
cross the BBB in vivo. To circumvent this problem, PAMAM was func-
tionalized with PEG and SRL, a small, artificially generated peptide, and
was able to cross the BBB. After internalization by phagocytosis and
interaction with the low-density lipoprotein receptor-related protein
(LRP) on the BBB, PAMAMs functionalized with SRL were able to ef-
ficiently transfect neurons in vivo with a plasmid DNA coding EGFP
following their intravenous injection in the tail of mice (Zarebkohan
et al., 2015). Similarly, different peptides that present high brain pe-
netration, such as angiopep-2 (Ke et al., 2009), lactoferrin (Huang et al.,
2008) and transferrin (Huang et al., 2007), were used to transfect brain
cells in vivo. Thus, due to its possible functionalizations and increased
BBB permeation, PAMAM potentially has great promise in applications
as a gene-delivery vector in vivo.
3. Physical methods for transfection
Physical methods are a collection of nonviral techniques for cell
transfection that rely on physical stimulation to deliver and direct ge-
netic material inside the living cell (Table 2). Physical methods promote
reversible alterations in the cell plasma membrane or endocytosis to
Table 2
Physical methods for transfection.
Group Type/Helper Toxicity In vivo delivery method Efficiency
/Stability
BBB accessibility Most Prominent Applications
(references)
Electroporation In utero ↓ Intraventricular injection ↑ N/A Saito, 2006;Dal Maschio et al.,
2012;Szczurkowska et al., 2016
Exo utero ↓ Intraventricular injection ↑ N/A Akamatsu et al., 1999; Saba et al., 2003
Postnatal ↓ Intraventricular injection,
Stereotaxic micro injection
↑ N/A Boutin et al., 2008; Chesler et al.,
2008;Kitamura et al., 2008
Sonoporation Microbubbles → Systemic injection,
Intraventricular injection





↓ Lumbar intrathecal injection,
Stereotaxic injection
→ – Song et al., 2010;Soto-Sanchez et al.,
2015
↑high / →medium / ↓low / +yes / -no / N/A-information not available.
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allow the direct passage of the molecules of interest into the cell, either
alone or with the support of chemical carriers, as described above
(Fig. 2). Physical stimulations can, at least in part, overcome many of
the side effects linked to biochemical or viral techniques. In particular,
the lack of toxicity, the lack of limitations on the length of the coding
sequence, and the low costs are among the main advantages. Physical
methods have outstanding experimental value in basic brain research.
On the other hand, their potential translational application in gene
therapy is heavily hampered by the invasiveness of their procedures
(e.g., the application of strong electric fields and intraventricular in-
jections) and their low efficiency when DNA delivery is performed
systemically (e.g., reduced brain accessibility through the BBB).
The first successful in vitro gene transfer supported by physical sti-
mulation was performed in 1980 with transfers into mouse glioma cells
by electroporation. The same approach was used for the first in vivo
transfection in skin cells of mice (Titomirov et al., 1991). Over the
years, other physical methods were proposed for in vivo gene transfer,
including magnet-assisted transfection (Mah et al., 2002b; Scherer
et al., 2002) and ultrasound application (Sheyn et al., 2008).
3.1. Electroporation
The electroporation technique was already used in vitro in the 1980s
(Neumann et al., 1982; Potrykus et al., 1985; Potter, 1988) as an acute,
quick, easy, highly efficient, low cost and mostly nontoxic procedure to
transfect bacteria and most cell types and to create transgenic plants.
Electroporation enables the transfection of large, highly charged mo-
lecules that cannot passively diffuse across the lipophilic cell membrane
by creating temporary water-filled holes in the membrane (20–120 nm
in diameter; (Chang and Reese et al., 1990)) through the application of
a series of electric-field pulses. Moreover, application of the electric
field also directs the charged molecules for transfection towards the
anode side, thus driving them in the desired direction towards the area
where the cells of interest are located. Conveniently, once the exposure
to the electric pulse is completed, the cell membrane reorganizes by
closing the temporary hydrophilic pores and returning to its physiolo-
gical structure, which traps the exogenous material inside the cell.
Recently, the electroporation technique has evolved into diverse ap-
plications in vivo (in and ex ovo, in and ex utero, as well as postnatal
electroporation) with one of the main advantages being the fast onset of
expression of the protein encoded by the transfected DNA. In general,
all the in vivo electroporation methods for the CNS share the same
concept: the DNA solution is injected into the lumen of the CNS ven-
tricular system. Indeed, at the interface between the lumen of the
ventricular system and the brain, there is a neuroepithelium where the
neuronal progenitors of different brain areas are located. Thus, fol-
lowing exposure to an electric field applied by a multipolar electrode,
negatively charged DNA is directed towards the positively charged
electrode and incorporated in the specific populations of neuronal
progenitor cells. Those progenitors will generate newly born neurons
committed to different brain areas, where the neurons will start mi-
grating upon birth, eventually allowing transfection of those discrete
brain regions.
3.1.1. In utero, exo utero and postnatal electroporation
In vivo electroporation was applied as a gene transfer method in
1997 in chick embryos in ovo (Muramatsu et al., 1997). Just four years
later, the first CNS transfections of mouse and rat embryos were per-
formed using in utero and exo utero electroporation (Fukuchi-Shimogori
and Grove et al., 2001; Saito and Nakatsuji, 2001; Tabata and
Nakajima, 2001).
The in utero electroporation (IUE) technique is based on the direct
injection of exogenous nucleic acids into the ventricular system of
embryos through the uterine wall of a pregnant dam. Then, the electric
Fig. 2. Physical methods of gene delivery.
Electroporation-mediated gene transfer (left)
enables the directional guidance of plasmids
carrying the negatively charged DNA of in-
terest towards the positive pole of the elec-
trode. At the same time, electroporation causes
destabilization of the structure of the cell
membrane, creating temporary pores in its
surface and allowing the plasmid to enter the
cell. The plasmid is then transported to the
nucleus. Sonoporation-mediated gene transfer
(middle) occurs by ultrasound application,
which promotes destabilization of the cell
membrane in the presence of oscillating mi-
crobubbles. During this process, the plasmid
contained in the microbubble mixture enters
the cell and is then transported to the nucleus.
Magnet-assisted transfection (right) is mediated
by magnetic field oscillations that guide and
promote endocytosis of the magnetic carriers
with attached DNA. In the cytoplasm of the
cell, the endosome undergoes degradation and
the released DNA enters the cell nucleus. After
DNA transcription, the mRNA exits the nucleus,
and it is translated into a protein in the cyto-
plasm.
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field is applied to the neuronal progenitors by means of two extra-
uterine forceps-type electrodes placed on the sides on the embryo head.
Since the injection of the nucleic acid solution occurs through the
uterine walls with no major damage to the uterus, the pregnant dam is
able to deliver the pups. This process allows both embryonal and
postnatal studies of the electroporated pups. High efficiency with the
two standard forceps-type paddle electrodes has been achieved for the
electroporation of pyramidal neurons in the rodent somatosensory
cortex (Saito, 2006). Since then, IUE has become the gold standard for
studies on cortical development ex vivo, both at the anatomical and
functional levels (LoTurco et al., 2009; Tabata and Nakajima, 2008;
Taniguchi et al., 2012). Over the years, researchers have achieved
targeting of many other brain regions by simply changing the orienta-
tion of the forceps-type electrodes. Indeed, by tilting the bipolar elec-
trode, it is possible to target the visual cortex (Cang et al., 2005; Mizuno
et al., 2007; Saito and Nakatsuji, 2001), hippocampus (Conrad et al.,
2010; Saito and Nakatsuji, 2001; Tomita et al., 2011), olfactory bulb
(Imamura and Greer et al., 2013), ganglionic eminence (Borrell et al.,
2005; Tanaka et al., 2006), thalamus (Haddad-Tovolli et al., 2013),
hypothalamus (Haddad-Tovolli et al., 2013), midbrain, amygdala
(Remedios et al., 2007; Soma et al., 2009) cerebellum (dal Maschio
et al., 2012; Kita et al., 2013; Szczurkowska et al., 2016; Yamada et al.,
2014), spinal cord (Saba et al., 2003) and brainstem (David et al.,
2014), but with a highly variable degree of efficiency (dal Maschio
et al., 2012; Szczurkowska et al., 2016). Recently, the addition of a
third electrode to the standard electroporation configuration has en-
abled highly reliable bilateral transfection of the hippocampus; the
prefrontal, motor and visual cortices; and the cerebellum in a single
electroporation episode (dal Maschio et al., 2012; Szczurkowska et al.,
2016, 2013). Notably, although transfection is confined to a specific
brain region and although not all cells in that region are transfected,
successful behavioral studies have been performed. For example, ani-
mals have been transfected in utero with DISC1 cDNA, leading to am-
phetamine hypersensitivity (Vomund et al., 2013), and DCX KO mice
have been transfected with DCX cDNA, leading to rescued epileptic-
seizure susceptibility (Manent et al., 2009). Moreover, IUE has also
been used in studies on psychiatric disorders, such as schizophrenia,
indicating the molecular pathways that lead to cognitive deficits
(Kamiya, 2009; Taniguchi et al., 2012).
One of the possible variations of the IUE technique is exo utero
electroporation (EUE). In this case, during surgery, embryos are re-
moved from the uterus. After DNA injection and delivery of the electric
field with the forceps-type electrodes, the embryos are placed back
inside the abdominal cavity of the dam without stitching the uterine
walls. Since EUE guarantees better accessibility to the embryos than
IUE, difficult-to-reach structures, such as the rhombencephalon
(Akamatsu et al., 1999), spinal cord and caudal hindbrain (Saba et al.,
2003), can be transfected with higher precision. Exo utero electro-
poration is mostly used for studying prenatal stages, as development of
the embryos out of the uterus does not allow vaginal delivery. However,
for postnatal studies, it is possible to rescue the electroporated embryos
right before birth (E18.5) by Cesarean section, followed by immediate
fostering with a stranger mother. Nevertheless, this procedure carries
the risk of the pup’s rejection by the foster mother.
It is possible to use the same principle of IUE to transfect animal
brains after birth, enabling the study of postnatal brain development. In
early postnatal electroporation, DNA is delivered to the brain ventricle
or to the subventricular zone using a stereotactic microinjector (Boutin
et al., 2008; Chesler et al., 2008), and the animal’s head is conveniently
placed between the plates of the forceps-type electrodes. This process
allows transfection of the progenitors located in the lateral, septal, and
dorsal walls of the lateral ventricle, resulting in the transfection of
different types of olfactory bulb neurons (Boutin et al., 2008; Chesler
et al., 2008; De Vry et al., 2010; Fernandez et al., 2011; Sonego et al.,
2013).
Finally, in adult rodents (up to 3,5 months old), DNA can be injected
into the ventricle or directly into the targeted brain area to achieve the
selective transfection of specific brain regions without affecting neu-
rodevelopment. In the case of adult electroporation, the electric pulses
can be applied with the standard forceps electrode (Chesler et al., 2008;
Kitamura et al., 2008), or - for more precise and region-specific elec-
troporation - a needle-like electrode can be inserted directly in the
targeted brain region after local application of the DNA solution
(Tanaka et al., 2000; Zhao et al., 2005). Late postnatal electroporation
has been used to target the dentate gyrus (DG; (De Vry et al., 2010))
and the CA1 region (Tanaka et al., 2000) of the hippocampus, the
prefrontal cortex (Zhao et al., 2005), the barrel cortex (Kitamura et al.,
2008), and the cerebellum (Kitamura et al., 2008).
3.2. Sonoporation
Sonoporation takes advantage of temporary pores created in the cell
membrane by ultrasound (US) exposure. The uptake of the DNA carriers
during exposure to US occurs by mechanical stress, which causes en-
docytosis and/or large membrane wounds that are later closed by en-
dogenous vesicle-based repair mechanisms (Fig. 2; Escoffre et al.,
2013). US pulses can be delivered on their own, but their delivery in
combination with a local application of microbubbles increases the
efficiency of transfection (Taniyama and Morishita, 2006). Indeed,
microbubbles are gas-filled structures (1–8 μm in diameter) that can
react to the ultrasound waves by sequential expansion and compression
(Lentacker et al., 2014), causing their own local oscillation close to the
cell membrane and increasing the permeability to exogenous material
(e.g., DNA). Moreover, the physicochemical composition of the micro-
bubbles can increase their chances of binding or capturing DNA. In
particular, the most commonly used microbubbles are proteins, lipids
or polymers (see chemical methods above). So far, the most suitable
solution for microbubbles comprises cationic lipids, which can easily
bind negatively charged plasmid DNA and are easily disrupted by US.
Although sonoporation is a promising technique that is well estab-
lished for in vitro gene transfer (Fischer et al., 2006), its in vivo appli-
cation is hindered by the possible aversive reactions of live tissue to US
exposure (e.g., increased temperature and production of reactive
oxygen species; Juffermans et al., 2006; Wu, 1998). In the embryonic or
newborn mouse, brain ultrasound was nevertheless used to attempt
transfection of plasmid DNA in combination with microbubbles, both
by intraventricular injection and systemically. However, the transfec-
tion efficiency was relatively low, and 50% of the injected embryos
suffered from hydrocephaly (Endoh et al., 2002). On the other hand,
microbubble-enhanced ultrasound improved gene transfer to the sub-
ventricular zone after intraventricular injection in adult mice in vivo
(Tan et al., 2016).
3.3. Magnet-assisted transfection
Magnetism-based targeted delivery was first described almost forty
years ago (Widder et al., 1978) as a means to use magnetic micro- and
nanoparticles for drug delivery to the circulatory system in vivo. The
technique takes advantage of a magnetic field to direct magnetic na-
noparticles (MNPs) containing nucleic acids into the target cells. The
MNPs used as carriers are mostly composed of an iron oxide (magnetic)
core with an additional organic or inorganic coating (e.g., arabic gum
((Zhang et al., 2009), liposomes (Linemann et al., 2013), polymers,
peptides and ligands/receptors (Estelrich et al., 2015)). Coated MNPs
have major advantages (Chatterjee et al., 2001; Estelrich et al., 2015).
Moreover, due to their positively charged magnetic core, the binding of
negatively charged molecules (e.g., DNA) is a relatively fast and easy
process. Upon activation of the magnetic field, MNPs are drawn to-
wards the target cells, where they undergo endocytosis or pinocytosis,
followed by nucleic-acid release, leaving the membrane composition of
the target cell intact (Fig. 2).
In in vitro studies, magnetofection has been commonly used due to
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its simplicity and high efficiency (Scherer et al., 2002). The application
of a magnetic field, together with MNPs, is also a promising approach
for in vivo gene transfer due to its noninvasive nature, ability to direct
DNA to the region of interest and lack of toxicity. Nevertheless, mag-
netofection in the CNS is still in its infancy. Indeed, in one report de-
scribing MNPs functionalized with PEI that were administered in the rat
spinal cord after lumbar intrathecal injection (Song et al., 2010), the
experiment was not fully successful due to the dispersion of MNPs in the
cerebrospinal fluid after exposure to the magnetic field. On the other
hand, highly efficient and long-term magnetofection of complexes of
EYFP channelrhodopsin and MNPs for optogenetic applications in the
rat visual cortex in vivo has also been reported upon direct brain in-
jection (Soto-Sanchez et al., 2015).
4. Virus-mediated trasduction
Viruses are nanometric infective agents composed of a protein
capsid that protects their genetic material and, in some cases, a lipid
envelope derived from the host cell membrane that protects the capsid.
Viruses can therefore be classified as naked or enveloped based on the
absence or presence of this lipid structure, respectively. All viruses are
dependent on the host cell to successfully replicate: they hijack the
replication machinery of the host cell and guide it to replicate the viral
genetic material. Indeed, during laboratory synthesis of viral particles
for experimental applications, cells are first infected with the aim of
synthetizing high numbers of new viral particles that are subsequently
purified and used at a high concentration in future experiments (Farson
et al., 2004). Depending on the type of virus used for the transfection
during experimental applications, the genetic material can be in-
tegrated in the host DNA or can be temporarily expressed (Fig. 3,
Table 3). All cells can be infected by specific viruses (Koonin et al.,
2006), and it is the capsid itself or in some cases, the envelope protein
sequence and shape that determines what kind of cell a virus will infect,
a property called tropism. As the genetic material carried by a virus can
be modified or substituted by a synthetic construct altogether, viruses
have been widely utilized as a means to perform genetic manipulations
in live cells. Interestingly, the capsid can also be artificially modified,
thus generating viruses with a desired tropism for specific cell types
(Freire et al., 2015).
The use of viral vectors for gene delivery into living cells dates back
to 1976 when, for the first time, a DNA segment of a bacteriophage
lambda was transfected into mammalian cells using a Simian Virus 40
(SV40) vector (Goff and Berg, 1976). Since then, the use of viruses in
biological and biomedical research grew exponentially, and today, viral
vectors are the most powerful technique for gene delivery in vitro and in
vivo. The main advantages of the use of viral vectors are their extremely
high specificity towards a certain cellular type and the high efficiency
of reliable transfection. On the other hand, once engineered, the viral
particle has to be purified. Easy and fast purification protocols are
currently available. However, the process may sometimes damage the
genomic material (Kay et al., 2001). Moreover, the size of the construct
is limited by the packing capacity of the capsid. Furthermore, viruses
are administered via intrathecal or intraventricular injection, which is
extremely invasive (Artegiani and Calegari et al., 2013; Kotterman
et al., 2015a; Thomas et al., 2003). Finally, most viruses require several
days before transduction of the genetic material, although the precise
expression timing varies for each type of viruses (e.g., herpes simplex
peaks at 24 h following infection; adeno-associated viruses require ap-
proximately 3 weeks to peak, although the expression is already visible
as soon as 24 h following administration; Penrod et al., 2015;
Reimsnider et al., 2007). Unlike the other methods for gene delivery,
some viral vectors can lead to viral genetic material becoming stably
integrated into the host genome (e.g., Herpes Simplex viruses), which
makes viral vectors particularly suited for the transfection of dividing
cells. On the other hand, integrated viruses may be dangerous because
the integration may occur in undesirable zones of the genome, leading
to harmful mutations, which hinders their usage in biomedical research
(Thomas et al., 2003). Conversely, with some other viral vectors (e.g.,
adenoviruses), the genetic material remains in the nucleus as a so-called
episome. Thus, nonintegrative viruses are safer but are mostly suitable
Fig. 3. Virus-mediated transduction. A lenti-
virus (left) can carry RNA inside its capsid.
Contact with cell-specific receptors induces the
fusion of the capsid with the cell membrane,
followed by RNA release. In the cell cytoplasm,
the released RNA undergoes reverse transcrip-
tion, and upon transport to the nucleus, the
RNA is integrated with the host DNA.
Adenovirus infection (middle left) is mediated
by specific receptor binding on the cell mem-
brane, followed by endocytosis. Endosome de-
gradation then results in the release of the virus
capsid and lysosomal degradation of the en-
dosome. The released virus capsid binds to the
nuclear pore of the infected-cell nucleus, al-
lowing the introduction of the double-stranded
DNA inside the nucleus. Adeno-associated virus
infection (middle right) is mediated by receptor
binding on the host-cell surface and en-
docytosis. Endosome degradation results in the
release of single-stranded DNA. The single-
stranded DNA enters the nucleus and under-
goes a conversion to double-stranded DNA,
which can be either integrated in the host DNA
(and later transcribed) or can remain in the
host cell nucleus as nonintegrated viral DNA.
Herpes simplex virus-mediated gene delivery
(right) is the result of receptor binding and
fusion of the virus with the cell membrane of
the host cell. Inside the cell, the released capsid
binds to the nuclear pore and introduces double-stranded DNA into the nucleus to be transcribed. The viral DNA in the host cell nucleus is transcribed into mRNA.
The transcribed viral mRNA exits the nucleus, and it is translated into a protein in the cytoplasm of the host cell.
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only for nondividing cells, as the nonintegrated plasmid becomes too
diluted in rapidly dividing cells to give the desired level of transfection
(Kotterman et al., 2015a; Thomas et al., 2003). Here, we will review the
four main viral classes that have in vivo applications in basic and bio-
medical research.
4.1. Lentiviruses
Lentiviruses are enveloped viruses belonging to the class of retro-
viruses (viruses bearing RNA genetic material) with the unique char-
acteristic of being able to infect nondividing cells in a long-term
manner. Being in the class of viruses bearing RNA, these viruses rely on
retrotranscription to integrate their genetic material in the host genome
(Fig. 3). Retrotranscription involves transcribing RNA into DNA with
the help of a reverse transcriptase enzyme, which is encoded by the
virus genome. Although lentiviruses are efficient viral vectors used for
gene delivery, they were originally derived from pathogenic agents (i.e.,
human immunodeficiency virus, HIV). This hampers their use in vivo,
due to the risks of eliciting strong immunogenic responses or even re-
conversion to the wild-type pathogenic form (Cockrell and Kafri, 2007;
Mah et al., 2002a). One important step made towards the development
of safe lentiviral vectors was the substitution of the envelope protein of
pathogenic viruses with one derived from a different virus (most
commonly, vesicular stomatitis virus G glycoprotein, VSV-G), which
cannot successfully multiply after infection of the host cell and presents
a wider tropism (Artegiani and Calegari et al., 2013; Mah et al., 2002b).
Nevertheless, lentiviruses have been successfully used for efficient gene
delivery in vivo for a long time (Bonci et al., 2003; Li et al., 2016; Qiao
et al., 2016). Indeed, an HIV-based VSV-G-pseudotyped virus was used
for the first time in vivo in 1996 to stably transfect fully differentiated
neurons and glial cells and deliver β-galactosidase to the hippocampus
of adult rats for up to three months after inoculation, without any
evident immunogenic reaction. The stability of the infection depended
on integration of the viral genome into the host-cell genetic material
(Naldini et al., 1996a, b). Other applications in the CNS followed, and
lentiviral vectors injected intracranially were used to study the effect of
ApoE isoforms on amyloid plaque deposition in a mouse model, al-
lowing the determination of the isoform-specific effects of ApoE on the
amyloid burden in the hippocampus (Dodart et al., 2005). Moreover,
modifications of the envelope of lentiviruses allowed preferential tar-
geting of discrete populations of cells in the CNS with high flexibility.
For example, lentiviruses pseudotyped with a modified envelope dis-
played anti-GLAST (an astrocyte-specific protein) IgG on their surfaces
and preferential astrocyte targeting in vivo (Fassler et al., 2013). In-
terestingly, due to their ability to infect fully differentiated cells, len-
tiviruses find widespread usage in the study and development of
therapies for neurodegenerative diseases, such as Parkinson’s (Azzouz
et al., 2004; Bensadoun et al., 2000; Yin et al., 2017) Alzheimer’s (Li
et al., 2017; Parsi et al., 2015; Tan et al., 2018) and Huntington’s dis-
ease (Cui et al., 2006; Schwab et al., 2017).
4.2. Adenoviruses
Adenoviruses (ADVs) are nonintegrating naked viruses that bear
double-stranded DNA. ADVs can transfect dividing and nondividing
cells with fairly high efficiency (Mah et al., 2002a). ADVs have been
successfully used in vitro to target neocortical and glial cells in culture
(Morelli et al., 1999; Smith-Arica et al., 2000; Southgate et al., 2008).
Nevertheless, their usage in vivo has been challenging due to their high
virulence (Thomas et al., 2003). To overcome this issue, ADVs have
been extensively engineered during the last 35 years with the aim of
generating nonimmunogenic vectors. The first generation of modified
ADVs had their viral genome deleted, generating replication-defective
ADVs; nonetheless, these ADVs still exhibited potent T-cell-related im-
munogenicity. These first-generation viruses showed potent toxicity to
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usage of these vectors still led to the successful treatment of glioma in
mice (Germano et al., 2003; Immonen et al., 2004; Lentz et al., 2012).
Due to their capacity to infect dividing cells, replication-defective ADVs
were also used to transfect neuronal precursors in the adult mouse brain
following intraventricular injections (Yoon et al., 1996). In a great leap
forward, safe ADV vectors were made with the development of helper-
dependent ADVs (HD-ADV; Thomas et al., 2003). The HD-ADVs lacked
any viral genes; thus, another virus (the helper virus) was needed to
carry the information for their replication during the laboratory pre-
paration of viruses for infection. This development enabled the synth-
esis of viral vectors with the ability to carry long constructs (up to 30
kB) that almost completely lacked virulence. Nevertheless, it is virtually
impossible to completely eliminate the helper virus during the labora-
tory purification procedure, although currently, the amount of con-
tamination can be reduced to less than 0,1%. This is a promising
achievement for future studies and applications using HD-ADVs (Kay
et al., 2001). Indeed, HD-ADV has been recently used to perform ma-
nipulations of the DNA in human pluripotent stem cells and induced
pluripotent stem cells (iPS), opening up the prospect of gene manip-
ulation of pluripotent stem cells for therapeutic applications (Mitani,
2014).
4.3. Adeno-associated viruses
Adeno-associated viruses (AAVs) are viruses strictly related to
ADVs. Indeed, AAVs were first isolated in 1965 as a contaminant in the
preparation of ADV (Atchison et al., 1965; Kay et al., 2001). AAVs have
a single-stranded DNA (ssDNA) genome composed of two genes, one for
their replication (rep) and one for their encapsulation (cap), even
though AAVs cannot replicate on their own. Similar to ADVs, AAVs
require a helper virus to multiply. The AAV genome remains in the
nucleus of host cells as an episome, or at a lower frequency, the AAV
genome stably integrates in the host genome. The natural replication
deficiency of AAVs in the absence of an HV gives them a natural safety
mechanism in in vivo applications (Kay et al., 2001; Mah et al., 2002b;
Samulski and Muzyczka, 2014; Yan et al., 2005). Indeed, these viruses
have never been associated with any pathology, and they are the most
studied viral vectors for gene delivery in vivo (Mah et al., 2000). Their
main drawback is their small packing capacity (not exceeding 5 kb),
which can nevertheless be increased by clever molecular biology tricks
(e.g., dividing the expression plasmid into two vectors and recon-
stituting a fully functional expression cassette after concatemerization
of episomes in the nucleus (Thomas et al., 2003)). So far, AAVs are the
method of choice for the study of in vivo brain physiology, since the
transfection can be stable for strikingly long times. Moreover, different
serotypes of AAVs can have different tropisms for discrete cell popu-
lations (Burger et al., 2004; Lentz et al., 2012). For example, an AAV
infection was stably expressed up to six months in the rat brain (Klein
et al., 1999) and up to 6 years in the bone marrow of nonhuman pri-
mates (Rivera et al., 2005). Moreover, due to their neurotropism and
their ability to be transported along the axon, AAV9 and AAVrh10 may
be used for the development of therapeutic approaches for local inter-
ventions of axonally connected structures (Choudhury et al., 2016b).
Finally, different AAV serotypes can transfect different cell types (e.g.,
astrocytes and oligodendrocytes) in the brain in vivo (Foust et al., 2009;
Lawlor et al., 2009). This transfection was achieved by shuffling
random pieces of the cap gene together to generate a large variety of
different cap proteins and later screening for specific tropism for dif-
ferent cell types. Indeed, gene shuffling of the heparin-binding domain
(HBD) in individual hybrid capsids of various AAV serotypes (AAV-type
2/type 8/type 9 chimera) helped in the creation of the AAV-DJ-derived
viral peptide library for cell-specific tropism in vivo in mice (Grimm
et al., 2008). The effect of the HBD on viral tropism was demonstrated
by transduction to diverse tissues, including the brain (Grimm et al.,
2008). Notably, cap-gene shuffling was also used to develop chimeric
AAVs with the remarkable ability to pass through the seizure-
compromised BBB in rats after kainic acid-induced seizures (Gray et al.,
2010). In addition to capsid shuffling, packaged plasmids with specific
promoters can also be used to achieve the goal of cell specificity (see the
discussion section for further information about promoters). Interest-
ingly, other AAV serotypes -when administered intravenously - were
unexpectedly shown to cross even an intact BBB in young and adult
animals (Bourdenx et al., 2014; Duque et al., 2009; Foust and Kaspar
et al., 2009; Foust et al., 2009). All these findings further fuel the in-
terest in basic and biomedical research on AAVs.
4.4. Herpes simplex viruses
The herpes simplex viruses (HSVs) are enveloped viruses bearing
double-stranded DNA genetic material. Their genome is relatively large,
having a length of approximately 152 kb and containing more than 80
genes. Because many of the genes are not essential for viral replication,
HSVs can carry at least 30 kb of nonviral DNA suitable for experimental
purposes (Kay et al., 2001). The main advantages of HSVs are their high
tropism for the CNS (for an unknown reason, especially sensory neu-
rons; Menendez and Carr, 2017) and the fact that after infection, the
HSV genome mostly remains in a latent form as a stable circular epi-
some in the nucleus of fully differentiated cells for a very long time
without eliciting any immunogenic response (Lentz et al., 2012). On the
other hand, their strikingly complex envelope makes the development
of cell-specific HSVs very challenging, although pseudotyping of HSV
with the VSV-G protein can reduce off-target transfection in vitro
(Andersen et al., 1982). Moreover, HSVs may still cause a massive ac-
tivation of the immune system by starting replication in the host cell.
This activation remains one of the main concerns for the use of HSV for
gene delivery in vivo. One way to avoid self-replication is to delete some
of the viral genetic material, generating nonself-replicating viral par-
ticles, which nevertheless need to be coupled to helper viruses for their
replication during preparation (Kay et al., 2001; Spaete and Frenkel,
1982). With this process, cytotoxicity was strongly reduced, and neu-
rons in culture were stably transfected for more than three weeks
(Krisky et al., 1998). Although HSVs have been widely studied in vivo to
treat glioblastoma in rodents (Nakashima et al., 2018; Ning and
Wakimoto, 2014; Wollmann et al., 2005), their application to the
transduction of neurons is still limited. Nevertheless, HSVs have been
already used to transfect the striatum (for up to 7 months) in a rat
model of Parkinson’s disease with genes necessary for the functioning of
dopaminergic neurons, providing significant recovery of the phenotype
(Sun et al., 2003).
5. Discussion
5.1. Challenges of in vivo gene delivery to the brain
The study of the CNS through acute genetic manipulations in vivo to
understand brain function in health and disease has always been a
challenging issue for scientists. First, there are technical issues related
to the inaccessibility of the brain due to the presence of the skull and
the BBB. Additionally, the great complexity of brain circuits (i.e., the
variety of neuronal and nonneuronal cell types) and network func-
tionality (i.e., the long- and short-range connectivity among different
brain regions) renders it difficult to establish causal relationships be-
tween genetic manipulations and cellular/behavioral outcomes in basic
research. Finally, the invasiveness of surgical procedures and viral
vector safety constitute additional challenges for translational appli-
cations. The various methods for in vivo gene manipulations highlighted
above present positives and negatives in regard to applications for basic
research or translational purposes in the difficult to access brain, which
we will discuss below.
5.1.1. CNS penetration
The first difficulty in achieving acute gene manipulations in the
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brain in vivo is the need to bypass the skull or the BBB. To this end,
tremendous efforts have been made to improve brain-delivery methods
or maximize vector permeability. One of the first and simplest ideas
developed in the past was the injection of DNA directly into the brain
area of interest. The first studies in this regard were performed in the
late 1980s and early 1990s (Breakefield and Geller, 1987), when dif-
ferent groups performed genetic manipulations by viral injection di-
rectly into the rodent retina and brain (Davidson et al., 1993; Palella
et al., 1989; Price et al., 1987). Furthermore, lipofectin-supported DNA
transfection, which overcomes the electrostatic repulsion of DNA by the
cell membrane, was also successfully performed by direct injection into
the mouse brain (Ono et al., 1990). Subsequently, chemical polymers
such as PEI were used to directly inject genetic material into the cortex,
hippocampus (Abdallah et al., 1996), spinal cord (Shi et al., 2003), and
SVZ (Lemkine et al., 2002) of rodents. Moreover, lipid vectors were also
effectively injected in the ventricles of early postnatal mice (Hassani
et al., 2005; Roessler and Davidson et al., 1994) for basic research or in
rodent glioblastoma to investigate possible therapeutic approaches
(Cikankowitz et al., 2017; Lagarce and Passirani, 2016; Pulkkanen and
Yla-Herttuala, 2005). Currently, physical methods, such as IUE and
EUE, are particularly suitable for studies of neurodevelopment, as DNA
can be directly injected into the large ventricles of developing embryos
and a strong electric field can be easily applied to the head of the
embryos. Indeed, embryos have no bony skull, which guarantees high
transfection efficiency (Saito, 2006; Szczurkowska et al., 2016). More-
over, the quick expression of transfected genetic material upon elec-
troporation also contributes to the successful application of this tech-
nique for neurodevelopmental studies. On the other hand, for viral
vectors, the main strategy used for their delivery in the brain remains
the direct intraparenchymal infusion of viral particles. Indeed, ventricle
injection requires a large quantity of viral material at high concentra-
tions, which may be difficult to obtain, as well as costly. Thus, viral
injection is more suitable for local transfection in the postnatal and
adult brain. Moreover, unlike electroporation, which becomes difficult
when the electric field needs to be delivered through the bony skull of
an adult animal, small amounts of viral vectors can be delivered by
direct stereotaxic injection in a specific brain region of adult animals,
following a minor craniotomy. Thus, viral vectors are the technique of
choice for the study of brain functionality at later postnatal ages, which
is also compatible with the fact that these vectors may require days
before driving efficient expression of the genetic material that they
carry.
Since direct injection in the brain - especially when considered for
translational applications - is still an invasive technique due to the
procedure itself and the risks of possible side effects related to the
surgical intervention, new strategies have been developed to bypass the
BBB in recent years. In particular, lipids and polymers supplemented
with helper lipids or functionalized with peptides to increase their BBB
permeation were successfully used with intravenous injection. For ex-
ample, dendrimers, PEI and nanoparticles have been functionalized
with PEG and other organic molecules to enable them to cross the BBB
(Zarebkohan et al., 2015). In addition, viral capsids have been en-
gineered to be more BBB permeable (Choudhury et al., 2016a, c;
Deverman et al., 2016; Zhang et al., 2011). Moreover, a portion of the
produced AAV particles remain associated with cell membranes (exo-
some-AAVs). Compared with AAVs, exosome-AAVs have a longer half-
life in the blood and increased BBB permeability (Hudry et al., 2016;
Maguire et al., 2012). Alternatively, nanoparticles have been con-
jugated to genetic material, and their small dimensions allow direct
intranasal delivery; thus, this method guarantees direct brain access
because it does not require BBB crossing (Yadav et al., 2016).
5.1.2. Transfection specificity in the brain
Another open issue to address when studying brain function and
possibly conceiving new treatments for brain disorders is the com-
plexity of brain networks: the ability to transfect a precise cell
population among many others has always been a challenge. The pos-
sibility of directing the electric field and thus the DNA in a specific
direction allowed the easy transfection of discrete populations of neu-
ronal progenitors of specific brain areas by IUE and EUE (dal Maschio
et al., 2012; Saito, 2006; Saito and Nakatsuji, 2001; Szczurkowska
et al., 2016). Nevertheless, while this method is very useful for in vivo
developmental studies, it is less suitable for studies performed in adult
animals, where chemical methods or viruses are the method of choice.
With these chemical or viral methods, the selection of an appropriate
cell-specific promoter upstream of the gene of interest enables the
transfection of discrete cell types (Murlidharan et al., 2014; Ojala et al.,
2015). For this purpose, several neuron- and glial-specific promoters
have been identified and tested for their ability to enable cell-specific
transduction (Hashimoto et al., 1996; Miura et al., 1990; Morelli et al.,
1999; Oellig and Seliger, 1990; Quinn, 1996). Nevertheless, the cell-
specific promoters tend to be too large to be packaged into viral vectors,
and the resulting gene expression is weaker than that driven by con-
stitutive viral promoters (e.g., CMV; Hioki et al., 2007; Shevtsova et al.,
2005). Thus, novel, smaller hybrid promoters that are able to efficiently
induce a strong, specific gene expression pattern have been generated
(Gray et al., 2011; Hioki et al., 2007; Kugler, 2016).
5.1.3. Combinations of the diverse in vivo transfection methods
To try and further overcome the difficulties related to modulation of
gene expression in vivo in the CNS in terms of brain accessibility,
transfection efficiency and/or space and time specificity, coupling of
the different delivery techniques has offered unquestionable ad-
vantages. For example, BBB opening by focused US was combined with
systemic administration of DNA bound to nanoparticles, resulting in a
noninvasive strategy for achieving safe, highly localized, robust, and
sustained transgene expression in the CNS (Mead et al., 2016). More-
over, a combination of US with the intravenous administration of naked
microbubbles - together with naked plasmid DNA (Shimamura et al.,
2004), AAVs (Hsu et al., 2013; Wang et al., 2017), liposomal-plasmid
DNA (Lin et al., 2015), liposome-shRNA-NGR complexes (Zhao et al.,
2018), polyethylene glycol-modified lipid-based bubbles (Negishi et al.,
2015), or folate-conjugated gene-carrying microbubbles (Fan et al.,
2016) - can induce reversible openings in the BBB and can increase the
transfection efficiency in rodents. Furthermore, a more efficient, brain
area-specific infection was achieved by coupling adenoviral vectors
with magnet-assisted transfection in the brain of rodent embryos in
utero (Hashimoto and Hisano, 2011; Sapet et al., 2012).
5.1.4. Combinations of in vivo transfection methods with newly emerging
techniques
The coupling of molecular biology tools, including newly emerging
techniques, with techniques for gene delivery in vivo also has tre-
mendous potential. For example, to achieve a transfection that is better
confined in time and space, IUE was coupled to the Cre/loxP system in
the study of retinal development (Matsuda and Cepko et al., 2007), and
AAV transfection was coupled to the tetracycline-controlled transcrip-
tional activation system (tet-on/off) in the study of the structure of the
neural circuits in the mouse neostriatum and primary somatosensory
cortex (Sohn et al., 2017). Moreover, both viral vectors and/or IUE
were successfully used to introduce optogenetic proteins, chemogenetic
receptors or voltage sensors into specific cell-types, cortex layers or
brain areas, allowing the study of neural circuits in vivo (Ghitani et al.,
2015). Furthermore, CRISPR-Cas9 technology, which allows genome
editing, regulation and visualization (Gilbert et al., 2013; Mali et al.,
2013; Qi et al., 2013), was recently coupled to IUE to study the role of
specific genes in brain development in vivo by knockout (Chen et al.,
2015; Cheng et al., 2016; Kalebic et al., 2016; Rannals et al., 2016a, b;
Shinmyo et al., 2016; Straub et al., 2014; Wang, 2018) or knock-in
(Tsunekawa et al., 2016). CRISPR-Cas9 technology coupled to IUE also
enabled the study of the subcellular localization of specific proteins by
inserting a sequence for a fluorescent protein into their encoding gene
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(Mikuni et al., 2016). Moreover, CRISPR-Cas9, despite its large size, can
be packaged in viral vectors for in vivo delivery, thus enabling robust
transfection in the adult mouse brain (Chen and Goncalves, 2016; Chew
et al., 2016; Ortinski et al., 2017; Schmidt and Grimm, 2015). Inter-
estingly, to increase Cas9 editing efficiency and decrease the risks of
off-target effects, different groups tested the delivery of a protein Cas9-
guide RNA (gRNA) complex by nucleofection (Kim et al., 2014; Lin
et al., 2014), cationic lipids (Zuris et al., 2015), lipid nanoparticles
(Wang et al., 2016; Yu et al., 2016) and cell-penetrating peptides
(Ramakrishna et al., 2014) in mammalian cells in vitro, thus opening the
possibility of a new delivery strategy to be applied in vivo. Indeed, the
protein Cas9/gRNA complex was recently coupled to IUE to study the
effect of the Tbr2 knockout in mouse neocortical progenitors (Kalebic
et al., 2016) and was injected in the hippocampus, dorsal striatum,
primary somatosensory cortex and primary visual cortex of adult mice
with a positive outcome (Staahl et al., 2017).
5.2. Specific challenges for translational research and possible therapeutic
applications
Gene therapy is defined as the transfer of genetic materials to spe-
cific target cells of a patient with the final goal of preventing or rescuing
a particular disease state (Mali, 2013). The main strategies for gene
therapy utilized so far entail the introduction of a replacement allele
into cells to compensate for the loss of function of a gene, the silencing
of a dominant mutant pathological allele and the introduction of
trophic factors or compensatory proteins (Choudhury et al., 2016c).
The first gene delivery in the human brain was performed by stereo-
tactic injection of retrovirus- and ADV-containing nuclear-targeted β-
galactosidase cDNA in 10 patients with malignant glioma (Puumalainen
et al., 1998). For the first time, this study evaluated the feasibility and
safety of virus-mediated gene transfer in human glioma in vivo, and it
showed a positive outcome (Puumalainen et al., 1998). Since then, due
to the therapeutic benefits and the safety found in subsequent clinical
trials, gene therapy has become a possible option for clinical inter-
vention in some otherwise terminal or severely disabling conditions
(Naldini, 2015). Indeed, in recent years, a large effort has been put into
continuously improving gene-delivery methods, and currently, more
than 2000 approved gene-therapy clinical trials have been conducted or
are ongoing worldwide (http://www.abedia.com/wiley/).
However, the vast majority of the gene-therapy clinical trials so far
have addressed cancer (64,5%), with neurological diseases representing
only 1.8% of the studies (http://www.abedia.com/wiley/). On the one
hand, this scarcity may be because the neuropathological mechanisms
underlying several neurological disorders are still poorly understood. In
this respect, in vivomethods for gene delivery that have been discovered
by emerging basic research may also hold great potential in the long
run for increasing our understanding of brain pathology. On the other
hand, the low number of gene-therapy clinical trials for brain disorders
may be due to the low availability of safe and efficient delivery vectors
that can cross the BBB or can be directly injected in the brain without
major complications. Nevertheless, the increasing prevalence of some
neurodevelopmental disorders (e.g., autism spectrum disorders;
Neggers, 2014) and of neurodegenerative disease (due to the increase in
the average age of the population; Johnson, 2015), in combination with
the identification of clearly causative mutations and the paucity of
standard pharmacological treatments for these brain disorders, high-
lights the need to search for alternative therapeutic approaches, in-
cluding gene therapy. Currently, AAV vectors have become the vehicle
of choice for in vivo gene transfer in most of the clinical trials targeting
the brain. Nevertheless, although some AAVs that are being currently
tested in animal models can effectively cross the BBB (Choudhury et al.,
2016b, c; Deverman et al., 2016; Zhang et al., 2011), so far, the AAVs
used in clinical trials are less permeable. Therefore, these AAVs are
commonly injected directly into the brain parenchyma, nevertheless
enabling long-term, relatively safe expression (Choudhury et al.,
2016c). For example, an ongoing phase I/II study is testing in-
traputaminal brain infusion of an AAV encoding human aromatic L-
amino acid decarboxylase as a possible treatment in subjects with
Parkinson’s disease (http://www.abedia.com/wiley/). Interestingly,
AAVs were recently engineered to be able to efficiently transduce
neural stem cells (Choudhury et al., 2016b; Kotterman et al., 2015b). To
avoid the risk of the surgery-related side effects of classic parenchymal
injection for virus delivery, a less invasive method, such as adminis-
tration into the cerebrospinal fluid via intracerebroventricular (ICV) or
intrathecal (IT) injection, has also been proposed (Choudhury et al.,
2016c). Nevertheless, these methods of application seem to be less ef-
fective in bypassing the BBB and less safe due to the activation of im-
munogenic responses (Choudhury et al., 2016c).
Despite the rapidly increasing usage of viruses for in vivo genetic
manipulations, they still present drawbacks (e.g., the possibility of
mutagenesis following viral integration in the host genome with the risk
of tumorigenesis, toxicity and immunogenicity, as well as the limited
genomic capacity). Thus, considerable interest has been recently con-
centrated on the development of nonviral vectors (e.g., lipids, nano-
particles and polymers) for translational purposes. Interestingly, some
clinical trials based on the use of lipofection to treat glioblastoma are
ongoing (http://www.abedia.com/wiley/), and the use of US combined
with microbubbles to deliver nanoparticles carrying the tumor-sup-
pressive miRNA-34a was recently evaluated in mice as a new possible
treatment (Vega et al., 2016). Moreover, the C2-9r peptide delivering a
siRNA against α-synuclein (Javed et al., 2016) and the US-mediated
delivery of the GDNF plasmid (Fan et al., 2016) or of nanomicrobubbles
containing the factor Nrf2 (Long et al., 2017) were recently tested in
rodents as a novel approach to treat Parkinson’s disease.
Finally, development of the CRISPR-Cas9 tool has opened new
avenues and possibilities for translational research and gene therapy.
Recently, some groups have started to investigate the potential of
CRISPR-Cas9 technology to recover mutations and correct monogenic
disorders in both cultured and in vivo stem cells (Maeder and Gersbach,
2016; Prakash et al., 2016). Moreover, CRISPR-Cas9 technology has
also been used to manipulate the cancer genome or epigenome for
therapeutic purposes in vivo. These changes include loss- or gain-of-
function mutations in oncogenes, tumor suppressor genes, and mod-
ulators of cellular transformation or drug response (Sanchez-Rivera and
Jacks, 2015). Nevertheless, the application of CRISPR-Cas9 technology
as a therapeutic approach for brain disorders has been slowed down, in
part, by difficulties in delivery due to its large dimensions (Walters
et al., 2015). Interestingly, recent promising results have been obtained
in a Huntington mouse model by reducing the mutant Huntingtin
(mHTT) gene expression through the injection of Cas9 and mHTT-gRNA
packaged in an AAV vector in the striatum (Yang et al., 2017).
5.3. Concluding remarks
Starting from the first attempts to deliver DNA to the difficult-to-
reach brain, much progress has been obtained in terms of the efficiency
of transfection, target specificity and safety in the CNS. This issue is of
great importance since the basic mechanisms of brain functions are far
from being resolved and since most brain disorders are still lacking a
cure. In this respect, the currently available variety of delivery methods,
which can be chosen to meet different experimental needs, and the
continuous effort to find new and/or more efficient and safer ways to
perform gene delivery in vivo will possibly aid basic research on animal
models and translational attempts. The coupling of different delivery
systems, such as chemical, physical and viral methods, together with
new technological revolutions, such as optogenetics, chemogenetics
and CRISPR-Cas9 technology, will further advance the field to further
broaden our understanding of the brain and address several neurolo-
gical disorders with new possible treatment options.
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